EoE
57 programs · 57 companies
Programs
57
Companies
57
Trials
46
MOAs
35
STINGagPRMT5iTROP-2 ADCVEGFiCD47iAnti-AβCAR-T CD19PCSK9iMeniniUSP1i
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-5389 | Preclinical | RET | ||
| GIL-9142 | Phase 1 | FXIa | ||
| Bemazumab | Phase 1 | VEGF | ||
| VRT-6833 | Preclinical | ALK | ||
| DNL-9555 | Phase 1/2 | KIF18A | ||
| Lisoosocimab | Approved | KIF18A | ||
| PRM-116 | NDA/BLA | C5 | ||
| SGM-7896 | Preclinical | CD3 | ||
| Zoricapivasertib | Phase 2 | HER2 | ||
| Fixatapinarof | Preclinical | PLK4 | ||
| Olpavorutinib | Preclinical | PARP | ||
| 460-4909 | Preclinical | PSMA | ||
| NIA-IIT-441 | Phase 2 | BET | ||
| IMM-7144 | Approved | PI3Kα | ||
| MOR-7494 | Phase 1 | SMN2 | ||
| Datocilimab | Approved | FLT3 | ||
| Miricapivasertib | NDA/BLA | DLL3 | ||
| RAP-6712 | NDA/BLA | PD-L1 | ||
| GLY-2161 | Phase 1/2 | PD-L1 | ||
| BSG-8809 | Approved | Nectin-4 | ||
| Kemanesiran | Phase 3 | CD19 | ||
| Gozerapivir | Phase 2 | CD38 | ||
| MYO-4326 | Phase 2/3 | BET | ||
| ORC-7732 | Phase 3 | JAK1 | ||
| Mirivorutinib | Phase 3 | CD38 | ||
| Lisolemzoparlimab | Approved | AuroraA | ||
| PRT-8732 | Phase 2/3 | PLK4 | ||
| KOD-8391 | Phase 2/3 | PARP | ||
| ALD-6159 | Phase 1 | Menin | ||
| Zenoderotide | Phase 1/2 | MALT1 | ||
| CYM-2446 | Phase 2/3 | MET | ||
| Rimacagene | Preclinical | BCL-2 | ||
| HOM-3477 | Approved | PSMA | ||
| Tixatuximab | Phase 3 | CD123 | ||
| Gelizumab | Phase 1/2 | PI3Kα | ||
| Daranesiran | Preclinical | IL-17A | ||
| Capiderotide | Phase 2 | Nectin-4 | ||
| ALM-7482 | Approved | C5 | ||
| ACE-3611 | NDA/BLA | CDK4/6 | ||
| POL-2929 | Phase 2/3 | GPRC5D | ||
| Sovarapivir | Preclinical | Cl18.2 | ||
| ALK-9856 | Approved | GIP-R | ||
| GRF-2905 | Phase 1 | Menin | ||
| Tixarelsin | Phase 2/3 | CFTR | ||
| Pexavorutinib | Phase 1/2 | Nectin-4 | ||
| Tezesacituzumab | Phase 2 | C5 | ||
| Ribozasiran | Phase 1/2 | C5 | ||
| TEV-6161 | Preclinical | PARP | ||
| TAT-IIT-251 | NDA/BLA | FXIa | ||
| AII-IIT-903 | NDA/BLA | GPRC5D | ||
| FRO-9633 | Phase 3 | SGLT2 | ||
| Doxatenlimab | Phase 2 | KRASG12C | ||
| Kemacapivasertib | Phase 2/3 | MDM2 | ||
| SYN-451 | NDA/BLA | SGLT2 | ||
| AMY-7405 | Phase 1/2 | GLP-1R | ||
| VCY-7974 | Phase 1 | CD20 | ||
| Gozefutibatinib | Preclinical | TIM-3 |
Trials (46)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT08854432 | GIL-9142 | Phase 1 | Completed |
| NCT07247227 | GIL-9142 | Phase 1 | Active |
| NCT06448755 | Bemazumab | Phase 1 | Recruiting |
| NCT06485180 | VRT-6833 | Preclinical | Terminated |
| NCT08293070 | Lisoosocimab | Approved | Not yet recr... |
| NCT04411353 | Lisoosocimab | Approved | Not yet recr... |
| NCT03040036 | Lisoosocimab | Approved | Completed |
| NCT08551907 | PRM-116 | NDA/BLA | Terminated |
| NCT07413112 | PRM-116 | NDA/BLA | Terminated |
| NCT06287834 | SGM-7896 | Preclinical | Completed |
| NCT08632065 | Fixatapinarof | Preclinical | Recruiting |
| NCT08880726 | 460-4909 | Preclinical | Recruiting |
| NCT04823192 | NIA-IIT-441 | Phase 2 | Active |
| NCT03308016 | IMM-7144 | Approved | Completed |
| NCT03425202 | MOR-7494 | Phase 1 | Completed |
| NCT04151919 | Datocilimab | Approved | Not yet recr... |
| NCT08110986 | BSG-8809 | Approved | Completed |
| NCT06192213 | BSG-8809 | Approved | Completed |
| NCT03622671 | Kemanesiran | Phase 3 | Completed |
| NCT07470998 | Gozerapivir | Phase 2 | Terminated |